Cardiovascular disease is the most common cause of death in people with diabetes. Many antihyperglycemic agents have been shown to improve CV outcomes. After completing this module, clinicians will be better able to alter the treatment options to reduce the CV risk in their patients with type 2 diabetes.
This program is developed in collaboration with Partners in Progressive Medical Education (PPME), and endorsed by Diabetes Canada.
This program has received an educational grant or in-kind support from Abbott Diabetes Care, Astra Zeneca, Boehringer Ingelheim (Canada) Ltd. and Eli Lilly Canada Inc., Janssen, Novo Nordisk and Sanofi.